We’re making biotech history

Messenger RNA is not new technology, but we are discovering new ways to use it to treat and prevent illnesses and diseases. Since our founding in 2010, we have worked to build the industry`s leading mRNA technology platform.

Our big moments

2010

Moderna incorporates

Moderna’s name combines the words "modified" and "RNA", which happens to contain the word "modern.”

2011

Operations started

Moderna begins research into the production of mRNA medicines. Stéphane Bancel joins as founding CEO.

2014

Expansion

New headquarters and labs open in Cambridge, Massachusetts.

2015

First human dose of flu vaccine

Moderna initiates first-in-human dose of an mRNA vaccine (mRNA-1440), an H10N8 flu vaccine candidate.

2016

New lease signed

Lease signed to build 200,000 sq ft GMP mRNA clinical manufacturing facility in Norwood, MA

2017

First human dose of multivalent vaccine

Moderna initiates first-in-human dosing for mRNA-1653, a combination vaccine with the potential to protect against more than one disease – human metapneumovirus (hMPV virus) and parainfluenza virus.

2018

New facility opens

Moderna opens its state-of-the-art clinical development site in Norwood, MA.

2019

First antibody encoded by mRNA

Moderna announces dosing of the first antibody encoded by mRNA in a clinical trial.

2020

CDC recommendation

The U.S. Centers for Disease Control and Prevention votes to recommend the use of the Moderna COVID-19 vaccine in people 18 years of age and older in the U.S.

2022

Moderna receives full approval for COVID-19 vaccine by U.S. FDA

The U.S. Food and Drug Administration (FDA) approved the Biologics License Application (BLA) for SPIKEVAX (COVID-19 Vaccine, mRNA) to prevent COVID-19 in individuals 18 years of age and older in the U.S.

RNA Technology for Clinical trials - Medical / Health Care - Clinical Services

Contact supplier